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Reliable, noninvasive methods for diagnosing and prognosing sinusoidal obstruction syndrome (SOS) early
after hematopoietic cell transplantation (HCT) are needed. We used a quantitative mass spectrometryebased
proteomics approach to identify candidate biomarkers of SOS by comparing plasma pooled from 20 patients
with and 20 patients without SOS. Of 494 proteins quantiﬁed, we selected 6 proteins (L-Ficolin, vascular cell
adhesion molecule-1 [VCAM1], tissue inhibitor of metalloproteinase-1, von Willebrand factor, intercellular
adhesion molecule-1, and CD97) based on a differential heavy/light isotope ratio of at least 2 fold, information
from the literature, and immunoassay availability. Next, we evaluated the diagnostic potential of these 6
proteins and 5 selected from the literature (suppression of tumorigenicity-2 [ST2], angiopoietin-2 (ANG2),
hyaluronic acid [HA], thrombomodulin, and plasminogen activator inhibitor-1) in samples from 80 patients.
The results demonstrate that together ST2, ANG2, L-Ficolin, HA, and VCAM1 compose a biomarker panel for
diagnosis of SOS. L-Ficolin, HA, and VCAM1 also stratiﬁed patients at risk for SOS as early as the day of HCT.
Prognostic Bayesian modeling for SOS onset based on L-Ficolin, HA, and VCAM1 levels on the day of HCT and
clinical characteristics showed >80% correct prognosis of SOS onset. These biomarkers may provide oppor-
tunities for preemptive intervention to minimize SOS incidence and/or severity.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic cell transplantation (HCT) is a potentially
life-saving treatment for many patients with inherited dis-
orders and hematologic malignancies. However, its practicaldgments on page 1745.
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ty for Blood and Marrow Transplantation.use is impeded by the risk of serious adverse events,
including sinusoidal obstruction syndrome (SOS, the now-
preferred name for veno-occlusive disease occurring after
HCT or chemotherapy). Although the overall incidence and
severity after allogeneic HCT have decreased in recent years,
SOS is still a life-threatening liver injury complication with
greater than 80%mortality in severe cases, and SOS affects up
to 20% of allogeneic HCT recipients in some centers [1-5]. SOS
can also occur after intense chemotherapy when either the
chemotherapy or radiation induces both systemic inﬂam-
mation and tissue damage, particularly to the sinusoidal
A. Akil et al. / Biol Blood Marrow Transplant 21 (2015) 1739e17451740endothelial cells of the hepatic acinus [6-8]. In addition, SOS
can occur after the use of drugs, such as gemtuzumab ozo-
gamicin, inotuzumab ozogamicin, and after the combination
of tacrolimus and sirolimus under certain circumstances
[9-12].
SOS typically occurs between the ﬁrst and third weeks
after HCT but it may occur later, and it is often clinically
indistinguishable from other causes of weight gain and res-
piratory distress, particularly in children (eg, cytokine storm
syndrome and idiopathic pneumonia syndrome), or other
causes of abdominal pain and jaundice (eg, graft-versus-host
disease [GVHD] of the gastrointestinal tract or liver) [4].
Diagnosis of SOS is made according to 2 clinical criteria scales
(Baltimore [13] and Seattle [6]) that measure different
degrees of liver dysfunction and weight gain. Abdominal
ultrasound showing a reversal of the sinusoidal ﬂow is
commonly used to conﬁrm the diagnosis. However, these
clinical criteria and reversal of the sinusoidal ﬂow are late
events in the pathology of the disease. The investigational
drug deﬁbrotide (Gentium/Jazz Pharmceutical, Palo Alto, CA)
has shown the most promising results in several clinical
trials [5,14]. However, treatment with deﬁbrotide carries
signiﬁcant risks, particularly of severe hemorrhage, when
given late in the disease course. Therefore, a noninvasive
method for early and accurate diagnosis of SOS is urgently
needed [15].
Although a few potential biomarkers for SOS have been
identiﬁed based on hypothesis-driven testing, there is still
no validated blood test for SOS. Therefore, in the present
study, we applied a quantitative mass spectrometry (MS)e
based proteomics discovery approach to identify potential
biomarkers for SOS and then used immunoassays to test the
diagnostic value of 11 candidate biomarkers. These analyses
led to the identiﬁcation of a reliable biomarker panel spe-
ciﬁc for SOS that can be used in the diagnosis and man-
agement of patients with this disorder. Most importantly,
given the high mortality rate associated with severe SOS
and the lack of a therapeutic measure with 100% efﬁcacy for
this life-threatening disease, we next focused on prognostic
markers that will afford opportunities for early preventative
care. Therefore, this study focused on both diagnostic and
prognostic markers, and although they are potentially
interesting, markers predictive of disease severity, response
to treatment, and nonrelapse mortality are beyond the
scope of this study.MATERIALS AND METHODS
Patients and Samples
Three cohorts of HCT patients were included in this study (discovery,
training, and independent veriﬁcation cohorts). Patients were treated at the
University of Michigan, Indiana University, and University of Barcelona. All
patients or their legal guardians provided written informed consent, and the
collection of samples for studying post-HCT complications was approved by
the institutional review boards of the University of Michigan, Indiana Uni-
versity, and Hospital Clinic of the University of Barcelona. Heparinized blood
samples were collected before or on the day of HCT, then weekly for 2 to
4weeks after allogeneic HCT, and, in some centers, at the time of the onset of
symptoms consistent with SOS.Proteomics Analysis
The methods used for sample preparation, protein fractionation, MS
analysis, protein identiﬁcation, and quantitative analysis of protein con-
centrations during the intact protein analysis system have been previously
reported [16-18].
Immunoassays
Suppression of tumorigenicity-2 (ST2), angiopoietin2 (ANG2), L-Ficolin,
hyaluronic acid (HA), vascular cell adhesion molecule-1 (VCAM1), tissueinhibitor of metalloproteinase-1 (TIMP1), thrombomodulin, intercellular
adhesion molecule-1 (ICAM1), plasminogen activator inhibitor-1 (PAI-1),
von Willebrand factor (vWF), and CD97 concentrations were measured by
enzyme-linked immunosorbent assays (ELISAs). The antibodies pairs used
for these ELISAs were as follows: anti-ST2 (R&D Systems, Minneapolis, MN),
anti-ANG2 (R&D Systems), anti-L-Ficolin (Hycult Biotech, Plymouth
Meeting, PA), anti-HA (Corgenix, Broomﬁeld, CO), anti-VCAM1 (R&D Sys-
tems), anti-TIMP1 (R&D Systems), anti-thrombomodulin (Diaclone, Besan-
con, France), anti-ICAM1 (R&D Systems), anti-PAI-1 (eBioscience, San Diego,
CA), anti-vWF (American Diagnostica, Stamford, CT), and anti-CD97 (R&D
Systems).
For analysis, plasma samples were thawed and centrifuged at
12,000 rpm for 10 minutes to separate the clots at the bottom and lipids on
top from the plasma. Then 150-mL aliquots of each undiluted plasma sample
were transferred to individual wells of 96-well V-bottom plates. The plates
were wrapped in paraﬁlm and kept in a humid chamber at 4C throughout
the entire process, which did not exceed 96 hours. Capture antibodies were
reconstituted and diluted per manufacturers’ speciﬁcations or precoated
plates were used as recommended by the manufacturer. Then, 50 mL of
diluted antibodies were added to wells of 96-well high-binding half-well
plates, which were then sealed and incubated overnight. The next day, the
test plates containing the capture antibodies were washed and blocked with
speciﬁc manufacturer’s recommended blocking buffer. After additional
wash steps, 50-mL or 100-mL aliquots of plasma samples (dilutions listed in
Supplemental Table 1) were added in duplicate to the ELISA test plates. In
addition, 50-mL or 100-mL aliquots of reconstituted standard at different
concentrations (see Supplemental Table 1) were added in duplicate for the
preparation of 8-point standard curves, per the manufacturers’ protocols.
After addition of samples and standard solutions, the plates were sealed and
incubated for 2 hours at room temperature on a plate rotator at 300 rpm.
The ELISAs were completed by adding biotinylated detection antibodies
speciﬁc for each target followed by the enzyme horseradish peroxidase and
horseradish peroxidase substrate. The optical density of each well was read
using a plate reader set to 450 to 570 nm. For ELISA kits with precoated
plates, the manufacturers’ protocols were applied. The ELISAs were per-
formed in duplicate and sequentially, as previously reported [18-22].
Statistical Analysis
The statistical methods used for the Intact Protein Analysis System (IPAS)
were previously described [16-18]. Differences in characteristics between
patient groupswere assessedwith Kruskal-Wallis tests for continuous values
and chi-squared tests of association for categorical values. Protein concen-
trations from individual samples in the training and independent sets were
compared using unpaired t-tests. Receiver operating characteristic (ROC)
areas under the curves (AUCs) were estimated nonparametrically. Differ-
ences in median pre-HCT, day 0, þ7, and þ14 biomarker levels between
SOS and SOS þ patients were assessed using a Wilcoxon rank-sum test.
Additionally, we examined the differences in biomarkers trajectories over
time using a modeling approach (see Supplementary Methods).
Prognostic Bayesian Modeling
The plasma concentrations of 3 proteomic biomarkers (L-Ficolin, HA,
and VCAM1) on the day of HCT were used to evaluate their prognostic
performance for future occurrence of SOS onset. The clinical characteristics
also included in the analysis were age, gender, donor type (related or un-
related), donor match (matched or mismatched), transplantation period
(before or in 2005 or after 2005), transplantation number (1 or >1), con-
ditioning regimen (chemotherapy only or combined with irradiation),
busulfan (16 mg/kg) use in the conditioning (yes or no), and cyclophos-
phamide use in the conditioning (yes or no). Plasma protein concentrations
and clinical characteristics were used as attributes for the prognosis of SOS
onset. The naïve Bayes classiﬁer was selected for SOS onset prognosis
because of its simplicity and high classiﬁcation performance. Ten-fold cross-
validation was used to avoid over training, bias, and/or artifacts (see
Supplemental Methods). This naïve Bayes classiﬁer was developed with
Waikato Environment for Knowledge Analysis software v3.6.10 [23].
RESULTS
Proteomic Biomarker Discovery
We ﬁrst performed discovery proteomic analysis
comparing plasma pooled from 20 patients with SOS to
plasma pooled from 20 patients without SOS. The clinical
characteristics of patients in this discovery cohort are pro-
vided in Table 1. Of 494 proteins identiﬁed and quantiﬁed,
151 proteins showed at least a 2-fold increase in the heavy-
light isotope ratio, and 77 proteins showed a heavy-light
Table 1
Patients’ Clinical Characteristics
Characteristic Discovery Cohort Training Cohort Independent Veriﬁcation Cohort
SOS (n ¼ 20) SOSþ (n ¼ 20) P Value SOS (n ¼ 13) SOSþ (n ¼ 32) P Value SOS (n ¼ 22) SOSþ (n ¼ 13) P Value
Age, yr
Median (range) 43 (3-56) 43 (1-58) NS 45 (3-55) 16 (1-58) .02 29 (1-66) 8 (1-48) .06
Disease, n (%)
Malignant* 19 (95) 18 (90) NS 12 (92) 27 (84) NS 22 (100) 13 (100) NS
Nonmalignanty 1 (5) 2 (10) 1 (8) 5 (16) 0 (0) 0 (0)
Donor type, n (%)
Related 18 (90) 17 (85) NS 12 (92) 17 (53) .02 14 (64) 3 (33) .02
Unrelated 2 (10) 3 (15) 1 (8) 5 (16) 8 (36) 10 (77)
Donor match, n (%)
Matched 20 (100) 20 (100) NS 13 (100) 25 (78) .08 18 (82) 7 (54) NS
Mismatched 0 (0) 0 (0) 0 (0) 7 (22) 4 (18) 6 (46)
Conditioning regimen intensity, n (%)z
Full 20 (100) 20 (100) NS 13 (100) 32 (100) NS 16 (73) 13 (100) NS
With busulfan
(16 mg/kg, 4 days)
14 (74) 17 (90) 9 (69) 26 (81) 1 (5) 3 (23)
With TBI 2 (10) 1 (5) 2 (15) 4 (12) 8 (36) 6 (46)
GVHD prophylaxis regimen, n (%)
Tacro or CsA/MTX 19 (95) 18 (90) NS 12 (92) 23 (72) NS 5 (23) 5 (38) NS
With rapamycin 0 (0) 0 (0) 0 (0) 1 (3) 6 (27) 1 (8)
With MMF 0 (0) 0 (0) 0 (0) 7 (22) 4 (18) 4 (31)
Otherx 1 (5) 2 (10) 1 (8) 1 (3) 1 (5) 0 (0)
NA 0 (0) 0 (0) 0 (0) 0 (0) 6 (27) 3 (23)
Time after HCT to SOS onset, d
Median NA 14 NA NA 11 NA NA 9 NA
Range NA 4-37 NA 4-63 NA 5-23
Time after HCT to SOS sample acquisition, d
Median 14 14 NS 14 11 NS 14 11 NS
Range 7-41 4-37 7-41 4-63 7-14 5-23
Future acute GVHD 2-4, n (%)
Yes 0 (0) 0 (0) NS 0 (0) 14 (44) .004 0 (0) 6 (46) .0005
No 20 (100) 20 (100) 13 (100) 18 (56) 22 (100) 7 (54)
Time after HCT to GVHD onset, d
Median NA NA NA NA 33 NA NA 21 NA
Range 14-75 (11-46)
NS indicates not signiﬁcant; TBI, total body irradiation; Tacro, tacrolimus; CsA, cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil; NA, not
applicable.
* Malignant disease included acute leukemia/myelodysplastic syndrome (n ¼ 69), lymphoma (n ¼ 18), multiple myeloma (n ¼ 2), chronic leukemia (n ¼ 13),
myeloﬁbrosis (n ¼ 2), paroxysmal nocturnal hemoglobinuria (PNH) (n ¼ 2), neuroblastoma (n ¼ 3), rhabdoid tumor (n ¼ 1), and carcinoid tumor (n ¼ 1).
y Nonmalignant disease included severe aplastic anemia (n ¼ 2), thalassemia (n ¼ 3), sickle cell disease (n ¼ 2), chronic granulomatous disease (n ¼ 1), and
familial lymphohistiocytosis (n ¼ 1).
z Full-intensity conditioning regimens included cyclophosphamide/etoposide/carmustine (CVB), clofarabine (n ¼ 7), busulfan (Bu)/cyclophosphamide (Cy)
(n ¼ 35), BAC (Bu [16 mg/kg], cytarabine [8000 mg/m2], and Cy [120 mg/kg] [n¼ 31]), CyTBI (n ¼ 21), ﬂudarabine (Flu) or Clo þ Bu (16 mg/kg) (n¼ 6), busulfan/
melphalan (n ¼ 1), Flu/melphalan (n ¼ 1), carboplatin/etoposide/melphalan (n ¼ 4), carboplatin/thiotepa (n ¼ 2), CyFlu (n ¼ 4), and CyThiotepa (n ¼ 2).
x Other GVHD prophylaxis included Tacro/corticosteroids (n ¼ 3), MTX/corticosteroids (n ¼ 2), Tacro/MTX/corticosteroids (n ¼ 1).
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complete summary). From the identiﬁed proteins, we
selected 6 proteins for further analysis: L-Ficolin, VCAM1,
TIMP1, vWF, ICAM1, and CD97. These proteins were selected
based on the observation of at least a 2-fold increase or
decrease in the heavy-light isotope ratio, their involvement
in relevant pathway networks, other information from the
published literature indicating they may be involved in the
pathogenesis of SOS, and the availability of a sandwich ELISA.
In addition, 5 endothelial markers (ST2, ANG2, HA, throm-
bomodulin, and PAI-1) were measured based on previous
demonstrations of their involvement in SOS [8,24,25] or in
refractory GVHD [22,26].
Development of a Biomarker Panel for SOS Diagnosis
Using sequential ELISAs [20], levels of the 11 identiﬁed
candidate biomarkers were measured in plasma from a
training cohort of 45 patients: 32 SOS patients with active
disease at onset (days þ14 to þ21 after HCT) and 13
time-matched controls. We used diagnosis samples from
SOS þ patients that were taken at the time of SOS onset,
and we selected samples from SOS patients so that bothgroups of samples were balanced according to time of
acquisition. The clinical characteristics of patients in this
training cohort are described in Table 1. The SOS and
SOS þ groups were balanced for age, primary disease,
donor type (related versus unrelated), donor match, and
intensity of the conditioning regimen (all full intensity with
most receiving 16 mg/kg busulfan for 4 days or total body
irradiation). More than 90% of patients received GVHD
prophylaxis of methotrexate and tacrolimus (or cyclo-
sporine) of standard duration. We tested the value of these
proteins as diagnostic biomarkers of SOS using unpaired
t-tests and by calculating the AUCs of the ROCs, which
represent the false positive and true positive rates for every
possible level of a marker. Among the 11 proteins tested, 8
were found to be diagnostic biomarkers of SOS with P
values ranging from <.001 to .04 and with AUCs between
.91 and .70 (Figure 1). The composite ROC of the 5 best
diagnostic markers (ST2, ANG2, L-Ficolin, HA, and VCAM1)
had an AUC of .98 in this selected case/control training
cohort (Supplemental Figure 1). Addition of TIMP1,
thrombomodulin, and ICAM1 to the biomarker panel did
not improve this AUC value (data not shown). Because ST2
Figure 1. Diagnostic biomarkers of SOS according to the highest AUCs (.91 to .70) in the training cohort. Plasma biomarker concentrations measured by ELISA in
patients with SOS (SOSþ) and without SOS (SOS-) (A-H). The data are shown as mean  standard error of the mean (SEM). Unpaired t-test, signiﬁcant at P < .05. The
numbers beneath the SOS categories are the AUC percentages for each marker.
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GVHD [22], we evaluated its prognostic value in the
training and independent cohorts. In these 2 cohorts,
approximately 45% of SOS patients later developed GVHD
(median number of days to onset of 33 and 21 versus 11 and
9 for SOS in the training and independent cohorts,
respectively). ST2 plasma concentrations at day 14 after
HCT (when almost all SOS patients have already developed
clinical signs of SOS) did not differ between the SOS þ
GVHD and SOS þ GVHD þ groups, meaning that for SOS
cases, ST2 is a diagnostic marker of SOS and this is more
important than its prognostic value for future GVHD.Figure 2. Prognostic biomarkers of SOS before the clinical signs in the training coho
(SOSþ) and without SOS (SOS) at different days after HCT (0, þ7, þ14). The data
assessed with Wilcoxon rank-sum test, signiﬁcant at P < .05. The numbers beneath th
when signiﬁcant.Prognostic Biomarker Panel for Risk Stratiﬁcation before
Clinical Signs of SOS
With the same training cohort, we next tested the prog-
nostic signiﬁcance of these biomarkers using protein levels
measured in samples taken before presentation of the clin-
ical signs (days 0 and þ7 after HCT). Three diagnostic bio-
markers were also prognostic before clinical signs were
apparent (L-Ficolin, HA, and VCAM1), and the corresponding
AUC values for biomarker values on the day of HCT were
between .84 and .70 (Figure 2). Modeling of these bio-
markers’ trajectories showed signiﬁcant differences between
the SOS and SOS þ groups (Supplemental Figure 2).rt. Plasma biomarker concentrations measured by ELISA in patients with SOS
are shown as mean  standard error of the mean (SEM). Median differences
e SOS categories are the AUC percentages for each marker and days after HCT
Figure 3. Prognostic biomarkers before the clinical signs of SOS in the independent cohort. Plasma biomarker concentrations measured by ELISA in patients with SOS
(SOSþ) and without SOS (SOS) at different days after HCT (-7, 0, þ7, þ14). The data are shown as mean  standard error of the mean (SEM). Median differences
assessed with Wilcoxon rank-sum test, signiﬁcant at P < .05. The numbers beneath the SOS categories are the AUC percentages for each marker and days after HCT
when signiﬁcant.
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We also tested the diagnostic and prognostic values of the
biomarkers in an independent cohort of 35 patients (13 pa-
tients with SOS and 22 patients without SOS). The clinical
characteristics of patients in this independent cohort are
presented in Table 1 and were similar to the clinical charac-
teristics of the training cohort. Despite the small sample size,
the results further validated L-Ficolin, HA, and VCAM1 as
diagnostic markers (AUC: .88, .81, and .81, respectively). We
next tested L-Ficolin, HA, and VCAM1 as prognosticmarkers of
SOSwith samples taken before the appearance of clinical signs
of SOS. L-Ficolin and HA also stratiﬁed patients at risk for SOS
as early as the day of HCT in this independent cohort
(Figure 3). Modeling of these biomarkers trajectories showed
signiﬁcant differences between the SOSþ and SOS groups
for L-Ficolin and HA but not for VCAM1 (Supplemental
Figure 3). Notably, for most patients in this cohort, in addi-
tion to the day 0 and day 7 samples, samples collected before
the conditioningwere included, and plasma levels of L-Ficolin,
and HA measured before transplantation did not differ be-
tween the SOS and SOS þ groups. Therefore, these results
strongly suggest that levels of these biomarkers are altered
during the conditioning regimen and before the appearance of
clinical signs of SOS, as they can be detected as early as the day
of HCT.
Prognostic Bayesian Modeling
Three data subsets were evaluated for model building.
Subset 1 was an imbalanced dataset (8 SOS versus 20
SOSþ) that included some missing day 0 biomarker infor-
mation, subset 2 was a balanced dataset (11 SOS versus 13
SOSþ) that included complete clinical and biomarker infor-
mation, and subset 3 was a balanced dataset (21 SOS versusTable 2
Naïve Bayes Classiﬁer Results Stratiﬁed by Ten-fold Cross-Validation
Clinical Characteristics
þ Biomarkers
Biomarkers Clinical
Characteristics
Correct prognosis 83.3% 70.8% 58.3%
ROC AUC (Yes) .90 .83 .61
False positive 1 1 4
False negative 3 6 620 SOSþ) that included some missing day 0 biomarker in-
formation. The balanced subset 2 with no missing attribute
information was selected to build the prognostic model. This
selection was based on results comparing the correct prog-
nosis between the 3 subsets tested and their corresponding
ROC AUCs (Supplemental Table 3). The clinical characteristics
of patients in this set are presented in Supplemental Table 4.
The model was evaluated using plasma concentrations of
biomarkers on day 0 with and without the addition of the
clinical characteristics. Table 2 shows the results (correct
prognosis and false negatives and positives) of the model
building using the selected data subset. The correct prog-
nosis was achieved in 83.3% of patients using the day
0 plasma biomarker concentrations in addition to clinical
attributes (ROC AUC ¼ .90).
DISCUSSION
Here, we present the ﬁrst use of a MS-based proteomics
discovery approach to identify biomarkers of SOS in plasma
samples from patients undergoing allogeneic HCT. In addi-
tion to identifying a panel of biomarkers that can be used for
SOS diagnosis, we identiﬁed 3 biomarkers that can be used to
evaluate the risk of developing SOS before clinical signs
appear, even as early as the day of HCT. Earlier hypothesis-
driven studies focused on markers of hemostasis and coag-
ulation, because microthrombus formation in the hepatic
sinusoid is 1 of the prominent clinical features of SOS. The
most extensively studied biomarker for SOS is PAI-1. Elevated
concentrations of PAI-1 have been shown to precede an in-
crease in bilirubin and to have diagnostic and prognostic
value [24]. Interestingly, in our analyses, with an AUC of only
.68, PAI-1 trended toward signiﬁcance as a biomarker of SOS,
but the corresponding P value did not reach signiﬁcance in
this patient set. Importantly, the diagnostic value of PAI-1
was less than that of 8 other markers.
More recent studies have focused on markers of endo-
thelial injury because another important and earlier mech-
anism of injury in SOS is thought to be conditioning-related
injury to the hepatic sinusoidal endothelium [27]. Elevated
levels of vWF, thrombomodulin, and ICAM1 before and early
after transplantation were shown to be useful in prognosti-
cating SOS in patients receiving sirolimus [25]. Among these
markers, both thrombomodulin and ICAM1 were identiﬁed
A. Akil et al. / Biol Blood Marrow Transplant 21 (2015) 1739e17451744as having diagnostic value in our study, although the levels of
these proteins were not found to be elevated in the early
period after HCT. vWF was identiﬁed in our proteomic
analysis with a heavy-light isotope ratio of 2.3, but vWF
levels were not signiﬁcantly different in patients with and
without SOS in our training set. One possible reason for this
discrepancy between our results and those of study from the
Dana Farber Cancer Institute is that we did not include pa-
tients treated with sirolimus and the mechanism of injury
induced by sirolimus to the endothelium may be different
from the mechanism on injury induced by the conditioning
regimen, as proposed in their study [25].
Known risk factors for SOS development are speciﬁc
conditioning agents (particularly busulfan at 16 mg/kg
[4 days] and to a lesser degree, cyclophosphamide) or total
body irradiation as well as more than 1 HCT, allogeneic HCT,
unrelated donor HCT, pre-existing liver disease or radiation
to the abdomen, use of the combination of tacrolimus/
rapamycin for GVHD prophylaxis, or the use of gemtuzumab
ozogamicin or inotuzumab ozogamicin [9-12]. In our
different cohorts, only 1 allogeneic HCT patient had a known
pre-existing liver condition, 3 patients had abdominal irra-
diation, and 2 patients received tacrolimus and rapamycin as
GVHD prophylaxis. These small sample sizes did not allow
for subanalyses. Thus, we used the following clinical criteria
in our analysis: age, gender, donor type (related or unre-
lated), donor match (matched or mismatched), trans-
plantation period (before or in 2005 or after 2005),
transplantation number (1 or >1), conditioning regimen
(chemotherapy only or combined with irradiation), busulfan
(16 mg/kg) use in the conditioning (yes or no), and cyclo-
phosphamide use in the conditioning (yes or no), and we
showed that the prognostic panel of biomarkers (L-Ficolin,
HA, and VCAM1) measured at day 0 of HCT signiﬁcantly
improved risk stratiﬁcation over these known clinical char-
acteristics, which alone provided a ROC AUC of .61 but in
combinationwith the prognostic biomarker panel provided a
ROC AUC of .90 (Table 2).
HA ismainly produced by cells of mesodermal lineage, and
homeostatic HA levels aremaintained by an efﬁcient receptor-
dependent removal mechanism present in the sinusoidal
endothelial cells of the liver. Systemic HA levels are, thus,
regarded as a direct marker of hepatic sinusoidal endothelial
cell function. Therefore, HA is a potentially relevant marker of
SOS as recently shown for SOS secondary to oxaliplatin-based
chemotherapy [8]. We validated HA as a diagnosis marker of
SOS with high speciﬁcity and sensitivity as well as a prog-
nostic factor at day 0 of HCT. Notably, using the same ELISA kit,
we observed HA concentrations after HCT that were 10-fold
greater than those observed after chemotherapy.
VCAM1 is a cell surface sialoglycoprotein expressed by
cytokine-activated endothelium that mediates leukocyte-
endothelial cell adhesion, and a role for VCAM1 in the
development of SOS has been suggested previously [3]. We
also hypothesized that 2 other markers of endothelial injury,
ST2 and ANG2, that have been shown to be elevated in re-
fractory GVHD [22,26] may also be elevated in SOS, which
has a more prominent endothelium component than GVHD.
Indeed, ST2 and ANG2 were found to be reliable biomarkers
for SOS diagnosis. However, they were not prognostic of the
occurrence of SOS in the early post-HCT period. These results
suggest that the mechanisms by which ST2 and ANG2 levels
are elevated after HCT, although activated 14 days before
onset of GVHD and relatively early in the course of GVHD, are
later events in SOS, occurring near the time of SOS onset.Interestingly, our proteomics analysis revealed an entirely
novel marker of SOS with strong diagnostic and prognostic
abilities: L-Ficolin. Furthermore, L-Ficolin’s mechanism of
action seems to implicate pathways in SOS other than those
related to hemostasis and endothelial injury. L-Ficolin is a
complement-activating pattern-recognition lectin involved
in the innate immune response and has recently been shown
to be involved in homeostatic clearance of mitochondria in
the liver [28]. In SOS patients, the concentrations of L-Ficolin
were decreased, suggesting that this homeostatic clearance
no longer happens efﬁciently. The identiﬁcation of L-Ficolin
demonstrates that the pathogenesis of SOS is multifactorial,
as previously hypothesized. Overall, the SOS biomarker panel
assembled in the present study includes molecules involved
in inﬂammation, innate immune response and homeostatic
clearance of mitochondria, endothelial injury, and hemos-
tatis. Furthermore, our ﬁndings suggest that activation of all
of these pathways precede clinical onset of SOS by at least
several days to as much as weeks.
The goal of the modeling was to assess whether the bio-
markers (L-Ficolin, HA, and VCAM1) can prognosticate the
possible future onset of SOS. The naïve Bayes algorithm
implemented in the data-mining software Waikato Envi-
ronment for Knowledge Analysis is a suitable choice for
addressing questions regarding future occurrence of an
event. In consideration of the actionable information that
would be available to clinicians for a patient at risk for SOS,
the model was built using the plasma concentrations of
biomarkers on day 0 and was tested with and without the
addition of clinical characteristics. The use of day 0 plasma
biomarker concentrations yielded a 83.3% correct prognosis
(ROC AUC ¼ .90), suggesting that the plasma concentrations
of L-Ficolin, HA, and VCAM1 at day 0 after conditioning could
be used for prognosis of SOS onset. The clinical attributes
alone were not useful, with only 58.3% correct prognosis
(ROC AUC ¼ .61). Combining the day 0 plasma biomarker
concentrations with clinical characteristics resulted in over
80% correct prognosis with a ROC AUC > .9. This observation
points to the added beneﬁt of individual attribute probability
for the overall outcome prognosis.
The high sensitivity and speciﬁcity of the biomarkers
identiﬁed in the present study make them useful for real-
time clinical testing and early clinical intervention. Howev-
er, our different patient sets were selected for case controls of
SOS. Thus, our results need to be conﬁrmed in a large, in-
dependent, prospective veriﬁcation cohort, ideally across
multiple institutions, to establish clinically useful cutoffs for
their future use in clinical trials [29]. The ultimate goal of
such trials is to ﬁnd a reliable biomarker panel that identiﬁes
patients at high risk for SOS who will beneﬁt from a pre-
emptive intervention using agents that target endothelial
injury and have been proven to be effective for treating SOS
[5,14].
In conclusion, our results demonstrate that SOS can
potentially be diagnosed based on a panel of biomarkers in
plasma as well as prognosticated as early as the day of HSC
infusion in patients. The naïve Bayes algorithm showed that
the L-Ficolin, HA, and VCAM1 plasma concentrations on day
0 after conditioning therapy are prognostic of SOS onset and
can potentially be used as prognostic proteomic biomarkers
for this disease. The identiﬁed markers represent several
pathways, including previously suspected pathways involved
in hemostasis and endothelial injury as well as novel path-
ways related to innate immunity and homeostatic clearance
of mitochondria. Once further validated in a clinical trial,
A. Akil et al. / Biol Blood Marrow Transplant 21 (2015) 1739e1745 1745these biomarkers could provide opportunities for preemp-
tive intervention to minimize the incidence and severity of
SOS.
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